New therapeutic options in sarcoidosis

Area of Science:

• Immunology
• Pulmonology
• Dermatology

Background:

• Corticosteroids are standard sarcoidosis treatment but cause significant side effects.
• Current second- and third-line treatments include hydroxychloroquine, immunosuppressants, and anti-TNF-α agents.
• Understanding sarcoidosis pathogenesis reveals new therapeutic targets.

Purpose of the Study:

• To review emerging therapeutic strategies for sarcoidosis.
• To highlight novel treatments beyond conventional therapies.
• To discuss the potential of new drug classes in managing sarcoidosis.

Main Methods:

• Review of case reports, small series, and prospective trials.
• Analysis of studies on novel drug classes targeting specific pathways.
• Evaluation of evidence for JAK inhibitors, mTOR inhibitors, and efzofitimod.

Main Results:

• Janus kinase (JAK) inhibitors, like tofacitinib, show encouraging results in skin and pulmonary sarcoidosis.
• mTOR inhibitors and efzofitimod (neuropilin-2 inhibitor) demonstrate potential in early studies.
• Other agents targeting CTLA-4, IL-6, NLRP3 inflammasome, GM-CSF, PDE-4, and statins are under investigation.
• Limited data exists for antifibrotic agents in fibrotic pulmonary sarcoidosis.

Conclusions:

• Novel therapeutic options are emerging for sarcoidosis management.
• Well-designed studies are crucial to validate these new treatments.
• Focus is needed on refractory sarcoidosis and patients intolerant to existing therapies.